Oxxides, Inc Harriman, NY

Antimony Trioxide, Oxidative stress, 8OHdG

Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism
Blog Cas9 Antibody Cas9 Lentivirus Cas9 Nickase Cas9 Nuclease Cas9 Protein

Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism

Cholangiocarcinoma (CCA) is the second most frequent main liver carcinoma with excessive levels of malignancy and mortality. Chemotherapy performs a key position within the remedy of CCA, nonetheless, the low chemotherapeutic effectivity results in a bottleneck.
So unraveling the potential mechanisms to reinforce the effectivity (lowered the dosage and enhanced the consequences of chemotherapy medicine) and figuring out different therapeutic methods in CCA are urgently wanted.
Right here, we discovered that, in CCA cells, when cisplatin (CDDP) displayed anti-tumor results, it activated 14-3-3ε concurrently, which in flip fashioned a survival mechanism through the phosphorylation of phosphatidylinositol 3-kinase/protein kinase B (PI-3K/Akt). Nonetheless, low concentrations of arsenic trioxide (ATO) might disrupt such survival mechanism and enhanced the effectivity.
For the molecular mechanisms, ATO attenuated 14-3-3ε at each transcriptional and post-transcriptional (ubiquitination degradation) ranges. Such repressive impact blocked the activation of PI-3K/Akt, and its downstream anti-apoptotic elements, B-cell lymphoma 2 (Bcl-2), and survivin. Collectively, our current research revealed that the synergistic results of ATO and CDDP could possibly be a novel strategy for enhancing the effectivity, which supplies an revolutionary therapeutic imaginative and prescient for the remedy of CCA.

Lengthy-Time period High quality of Lifetime of Acute Promyelocytic Leukemia Sufferers Handled with Arsenic Trioxide versus Chemotherapy

The principle goal of this research was to check the long-term health-related high quality of lifetime of sufferers with acute promyelocytic leukemia (APL) handled with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) versus ATRA plus customary chemotherapy.
Sufferers beforehand enrolled within the randomized managed trial APL0406 have been thought-about eligible for this follow-up research. The next patient-reported end result measures have been used: the EORTC QLQ-C30, the EORTC QLQ-CIPN20 and the SF-36. The prevalence of late comorbidities and well being issues was additionally assessed.
The scientific significance of variations was evaluated primarily based on predefined thresholds. This research was registered. 100 sixty-one out of 232 doubtlessly eligible sufferers have been analyzed, of whom 83 have been handled with ATRA-ATO and 78 have been handled with ATRA-chemotherapy. The median time since prognosis of the research pattern was Eight years.
The 2 largest clinically significant variations within the EORTC QLQ-C30 have been noticed for position functioning (Δ=8.4, 95% CI, 0.5 to 16.3) and dyspnea (Δ=-8.5, 95% CI, -16.Four to -0.7), favoring sufferers handled with ATRA-ATO.
With regard to the SF-36 outcomes, a clinically related higher bodily element rating (Δ=4.6, 95% CI, 1.Three to 7.8) was noticed in sufferers handled with ATRA-ATO, however this was not the case for the psychological element rating. The 2 teams confirmed comparable profiles within the scores of the EORTC QLQ-CIPN20 scales and within the prevalence of late comorbidities.
General, our findings counsel that the larger and extra sustained antileukemic efficacy of ATRA-ATO can also be related to higher long-term patient-reported outcomes than ATRA-chemotherapy.

New Bioactive Calcium Silicate Cement Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP)-A Systematic Assessment

Bioactive calcium silicate cement Mineral Trioxide Combination (MTA) has been used for years as a gold customary in intravital pulp remedy and specialist endodontic procedures.
Owing to flaws of the fabric, the producers have been making an attempt to reinforce and produce supplies displaying improved bodily, chemical and organic parameters. One of many new calcium-silicate cements primarily based on mineral trioxide mixture, nonetheless with out some flaws exhibited by the cement, is Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP).
The intention of the current paper was a scientific literature assessment regarding the MTA HP materials used these days in dentistry, as a assessment of its particular options. The current paper is the primary article offering a scientific literature assessment on MTA HP.
The intention of the current article is the higher understanding of MTA HP properties, which may support the decision-making course of in endodontic remedy.
Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism

Genetic Expression Screening of Arsenic Trioxide-Induced Cytotoxicity in KG-1a Cells Based mostly on Bioinformatics Expertise

Acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system, and leukemia stem cells are chargeable for AML chemoresistance and relapse. KG-1a cell is taken into account a leukemia stem cell-enriched cell line, which is immune to chemotherapy.
Arsenic trioxide (ATO) is efficient in opposition to acute promyelocytic leukemia as a first-line remedy agent, at the same time as remission induction of relapsed instances. ATO has a cytotoxic impact on KG-1a cells, however the mechanism stays unclear. Our outcomes demonstrated that ATO can inhibit cell proliferation, induce apoptosis, and arrest KG-1a cells within the G2/M part.
Utilizing transcriptome evaluation, we investigated the candidate goal genes regulated by ATO in KG-1a cells. The expression profile evaluation confirmed that the ATO had considerably modified gene expression associated to proliferation, apoptosis, and cell cycle. Furthermore, MYC, PCNA, and MCM7 have been recognized as essential hub genes by means of protein-protein interplay community evaluation; in the meantime, the expressions of them in each RNA and protein ranges are down-regulated as confirmed by quantitative polymerase chain response and Western blot.
Thus, our research means that ATO not solely inhibits the expression of MYC, PCNA, and MCM7 but additionally results in cell cycle arrest and apoptosis in KG-1a cells. General, this research offered dependable clues for bettering the ATO efficacy in AML

Ultrasonically assisted conversion of uranium trioxide into uranium(VI) intrinsic colloids

Beneath oxidizing situations, the corrosion of spent nuclear gasoline might result in the leaching of radionuclides together with soluble uranyl-based species. The speciation of the generated chemical varieties is complicated and the associated potential formation of colloidal species seems surprisingly poorly reported within the literature.
Their formation might nonetheless contribute considerably to the mobility of radionuclides within the surroundings. A greater data within the speciation and reactivity of those species seems notably related. This research describes the preparation and characterization of intrinsic uranium(vi) colloids from amorphous and crystalline UO3 in pure water assisted by 20 kHz ultrasound.
Within the presence of carbon monoxide stopping the sonochemical formation of hydrogen peroxide, ultrasonic remedy boosts the conversion of UO3 powder into (meta-)schoepite precipitates and yields very secure and notably concentrated uranium(vi) nanoparticles within the liquid part. Utilizing HR-TEM, SAXS and XAS strategies, we confirmed that the colloidal suspension consists of quasi-spherical nanoparticles measuring ca. 3.8 ± 0.Three nm and exhibiting a schoepite-like crystallographic construction.

Antimony Ingot, 99.9999%
GX7081-50 50
EUR 249.2

Antimony Ingot, 99.999%
GX8708-100 100
EUR 277.1

Antimony Ingot, 99.999%
GX8708-500 500
EUR 728.4

Antimony Pieces, 99.999%
GX7845-100 100
EUR 340.5

Antimony Pieces, 99.999%
GX7845-25 25
EUR 134.1

Antimony Pieces, 99.999%
GX7845-500 500
EUR 1218.8

Antimony Pieces, 99.9999%
GX8733-25 25
EUR 180.9

Antimony Pieces, 99.9999%
GX8733-250 250
EUR 751

Antimony Pieces, 99.9999%
GX8733-50 50
EUR 283.5

Antimony(III) sulfide
GX5942-500 500
EUR 164.8

Antimony(V) chloride
GX8478-250 250
EUR 200.6

Antimony potassium tartrate trihydrate
A100-2x25G 2 x 25 g
EUR 75.6

Antimony potassium tartrate trihydrate
A100-4x25G 4 x 25 g
EUR 100.8

Antimony(V) pentasulfide
GX8145-50G 50 g
EUR 211.2

Antimony(V) pentasulfide
GX8145-50 50
EUR 145.1

Antimony(III) oxide, 98+%
GX8352-500 500
EUR 128.1

Antimony(III) oxide, 99.99+%
GX8841-100 100
EUR 358.4

Antimony(III) oxide, 99.99+%
GX8841-25 25
EUR 169.5

Antimony(III) oxide, 99.9%
GX1943-250 250
EUR 685.9

Antimony(III) oxide, 99.9%
GX1943-50 50
EUR 228.1

Antimony tin oxide, 99.95 %
GX2870-1 1
EUR 1079.3

Antimony tin oxide, 99.95 %
GX2870-100 100
EUR 221.7

Antimony tin oxide, 99.95 %
GX2870-25 25
EUR 129.6

Antimony tin oxide, 99.95 %
GX2870-250 250
EUR 416.4

Antimony(III) iodide, 99.999%
GX5562-10 10
EUR 683.6

Antimony(III) fluoride, 99%
GX8250-250 250
EUR 129.6

Antimony(III) chloride, 99.99+%
GX1593-10 10
EUR 119.1

Antimony(III) chloride, 99.99+%
GX1593-50 50
EUR 407.4

Antimony(III) chloride, 99%
GX2593-250 250
EUR 129.6

Antimony tin oxide (ATO); 99,95 %
GX2461-1 1
EUR 1311.6

Antimony tin oxide (ATO); 99,95 %
GX2461-100 100
EUR 299.9

Antimony tin oxide (ATO); 99,95 %
GX2461-25 25
EUR 137.2

Antimony tin oxide (ATO); 99,95 %
GX2461-250 250
EUR 496.9

Antimony Powder -325 mesh, 99.5%
GX2647-100 100
EUR 107

Antimony Powder -325 mesh, 99.5%
GX2647-500 500
EUR 259.8

ICP Std Antimony 1000ug/mL in 1% HCl
PSB2A11 100ML
EUR 118.81

ICP Std Antimony 1000ug/mL in 10% HCl
PSB2A5 100ML
EUR 120.12

ICP Std Antimony 1000ug/mL in 20% HCl
PSB2B5 250ML
EUR 147.53

ICP Std Antimony 1000ug/mL in 10% HCl
PSB2C5 500ML
EUR 261.6

ICP Std Antimony 10000ug/mL in 10% HCl
PSB4A5 100ML
EUR 207.6

ICP Std Antimony 10000ug/mL in 20% HCl
PSB4B5 250ML
EUR 271.56

Antimony Shot 1-3 mm, 99.999%
GX5423-50 50
EUR 208.6

Antimony Shot 1-3 mm, 99.9999%
GX3665-10 10
EUR 110

Antimony Shot 1-3 mm, 99.9999%
GX3665-50 50
EUR 257.4

AAS Antimony Std 1000ppm in H2O
AASBH 500ML
EUR 106.8

AAS Antimony Std 10000ppm in H2O
AASBM 500ML
EUR 285.6

Antimony Rod 6 mm diameter, 99.999%
GX5626-50 50
EUR 505.1

Antimony Rod 8 mm diameter, 99.999%
GX9225-50 50
EUR 510

ICP Std Antimony 1000ug/mL in 6% Tart. Acid
PSB2B4 250ML
EUR 152.76

Antimony Powder max. 250 micron, 99.999%
GX3000-10 10
EUR 125.1

Antimony Powder max. 250 micron, 99.999%
GX3000-100 100
EUR 453

Antimony Powder max. 250 micron, 99.999%
GX3000-50 50
EUR 272.2

ICP Std Antimony 1000ug/mL in 1% HF + 5% HNO3
PSB2C4 500ML
EUR 265.04

ICP Std Antimony 10000ug/mL in 1% HF + 5% HNO3
PSB4A4 100ML
EUR 208.9

ICP Std Antimony 100ug/mL in 1% HF + 5% HNO3
PSB1A4 100ML
EUR 212.4

ICP Std Antimony 10000ug/mL in 6% Tart. Acid tr. HNO3
PSB4B4 250ML
EUR 236.31

ICP Standard Antimony Plus Tr HNO3 1000ug/ml
PSB2A4 100ML
EUR 120

Kinesis Hollow Cathode Lamp Antimony 37mm Std
CHR5943 EACH
EUR 334.23

Lead, Antimony alloy, 2.5-3.5% Sb, shot 2-3 mm
GX9319-1 1
EUR 120.5

Lead, Antimony alloy, 2.5-3.5% Sb, shot 2-3 mm
GX9319-500 500
EUR 87.4

Kinesis Hollow Cathode Lamp Antimony 50mm Standard
CHR5951 EACH
EUR 463.49

EP Reagent Conc to make Antimony Sb Sol. 1000ppm
5000400C 100ML
EUR 217.2

Antimony 1000 ug/g (1000 PPM) for AA and ICP 50 grams in Base Oil 20
ORG-SB8-2Z 50G
EUR 79.2

Kinesis Hollow Cathode Lamp Antimony 37mm unicam Coded
CHR5947 EACH
EUR 385.15

Kinesis Hollow Cathode Lamp Antimony 37mm Varian Coded
CHR5949 EACH
EUR 385.15

Kinesis Hollow Cathode Lamp Antimony 50mm PE AAnalyst (Lumina)
CHR5953 EACH
EUR 590.13

Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 500mL in 20% HCl
PLSB52X 500ML
EUR 210

Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 30mL in H2O / 0.6% Tart. Acid / Tr. HNO3
PLSB7-2M 30ML
EUR 34.8

Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 250mL in H2O / 0.6% Tart. Acid / Tr. HNO3
PLSB7-2T 250ML
EUR 111.6

Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 500mL in H2O / 0.6% Tart. Acid / Tr. HNO3
PLSB7-2X 500ML
EUR 144

Assurance Grade Antimony for AA and ICP 1000 ug/mL (1000 PPM) 125mL in H2O / 0.6% Tart. Acid / Tr. HNO3
PLSB7-2Y01 125ML
EUR 63.6

Assurance Grade Antimony for AA and ICP 10000 ug/mL (10000 PPM) 500mL in H2O / 6% Tart. Acid / 1% HNO3
PLSB7-3X 500ML
EUR 255.6

Assurance Grade Antimony for AA and ICP 10000 ug/mL (10000 PPM) 125mL in H2O / 6% Tart. Acid / 1% HNO3
PLSB7-3Y 125ML
EUR 116.4

Claritas PPT Grade Antimony for ICP-MS 1000 ug/mL (1000 PPM) 30mL in H2O / 0.6% Tart. Acid / Tr. HNO3
CLSB7-2M 30ML
EUR 50.4

Claritas PPT Grade Antimony for ICP-MS 1000 ug/mL (1000 PPM) 125mL in H2O / 0.6% Tart. Acid / Tr. HNO3
CLSB7-2Y 125ML
EUR 110.4

Antimonyl (potassium tartrate trihydrate)
HY-B1082 100mg
EUR 142.8

Potassium antimonyl tartrate trihydrate, 99.5+%
GX0998-100 100
EUR 102.4

Potassium antimonyl tartrate trihydrate, 99.5+%
GX0998-500 500
EUR 233

Triton Extraction Buffer(TEB), for Histon Extraction
T8300-100 100ml
EUR 151.2

Triton Extraction Buffer(TEB), for Histon Extraction
T8300-500 500ml
EUR 170.4

anti-MON1B
YF-PA17649 50 ug
EUR 435.6
Description: Mouse polyclonal to MON1B

1,3,5‐TRIOXANE
920024 each Ask for price

Anti-MON2 antibody
STJ118940 100 µl
EUR 332.4

Anti-MON1B antibody
STJ119697 100 µl
EUR 332.4

Anti-MON1A antibody
STJ119930 100 µl
EUR 332.4

Anti-Melanocortin Receptor 3 (extracellular) Antibody
A02841 200ul
EUR 793.2
Description: Rabbit Polyclonal Melanocortin Receptor 3 (extracellular) Antibody. Validated in IHC, WB and tested in Human, Mouse, Rat.

Trioxsalen
C4451-100 100 mg
EUR 151.2
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative.

Trioxsalen
C4451-250 250 mg
EUR 278.4
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative.

Trioxsalen
C4451-500 500 mg
EUR 374.4
Description: Trioxsalen has been reported to intercalate into DNA forming DNA single-strand adducts and interstrand crosslinks when activated with UV light.In vitro: Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative.

Trioxsalen
HY-B1157 500mg
EUR 308.4

Anti-MON1A (aa589-601) antibody
STJ72146 100 µg
EUR 430.8

Anti-MON1A (aa478-489) antibody
STJ72147 100 µg
EUR 430.8

2D Protein Extraction Buffer Trial Kit 1 x for 50mL
28943522 EACH
EUR 204

Indium antimonide, 99.999%
GX8407-10 10
EUR 555.4

Indium antimonide, 99.999%
GX8407-2 2
EUR 179.3

Rabbit Anti-Monkey IgG（h+l）
C020217-100mg 100mg
EUR 3162

Rabbit Anti-Monkey IgG（h+l）
C020217-1mg 1mg
EUR 181.2

mAb mouse anti-monkey IL-4
CT103 0.5 mg
EUR 312

mAb mouse anti-monkey IL-6
CT104 0.5 mg
EUR 312

mAb mouse anti-monkey IL-5
CT105 0.5 mg
EUR 312

mAb mouse anti-monkey IL-2
CT112 0.5 mg
EUR 312

mAb mouse anti-monkey CD3
CT161 0.5 mg
EUR 457.2

Rabbit Anti-Monkey IgG
FNSA-0099 500 uL
EUR 367.92
Description: Rabbit Anti-Monkey IgG secondary antibody

Gallium antimonide, 99.99%
GX0988-2 2
EUR 198.7

5X Bacterial Protein Extraction Reagent (Tris)
AKR-180 50mL
EUR 331.2
Description: The Cell Biolabs Bacterial Protein Extraction Reagents contain a gentle, nonionic detergent formulation which quickly extracts functional, recombinant protein from E. coli without mechanical disruption.

Anti-monkey CD3 antibody
STJ15100146 500 µl
EUR 210
Description: The anti-CD3 antibody is a useful tool for polyclonal activation of monkey T cells. Induction of cytokine secretion is dependent on number, nature and viability of accessory cells.

mAb mouse anti-monkey IFN-γ
CT101 0.5 mg
EUR 334.8

mAb mouse anti-monkey IL-10
CT107 0.5 mg
EUR 312

mAb mouse anti-monkey IL-13
CT109 0.5 mg
EUR 312

AR antibody
10R-2031 100 ul
EUR 483.6
Description: Mouse monoclonal AR antibody

AR antibody
70R-35838 100 ug
EUR 392.4
Description: Rabbit polyclonal AR antibody

AR Antibody
ABD6783 100 ug
EUR 525.6

AR Antibody
32572-100ul 100ul
EUR 302.4

AR Antibody
AF6137 200ul
EUR 420

AR Antibody
AF6927 100ul
EUR 420

AR Antibody
BF0349 200ul
EUR 540

AR Antibody
BF0418 200ul
EUR 540

AR Antibody
CSB-PA001975KA01HU- each
EUR 402
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100

AR Antibody
CSB-PA001975KA01HU-100ul 100ul
EUR 466.8
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100

AR Antibody
DF6783 200ul
EUR 420

AR Antibody
1-CSB-PA011255
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000

AR Antibody
1-CSB-PA011256
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000

AR Antibody
1-CSB-PA011257
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000

AR Antibody
1-CSB-PA011258
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

AR Antibody
1-CSB-PA006094
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000

AR Antibody
1-CSB-PA056943
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100
The proposed technique demonstrates the potential formation of environmentally related U(vi) colloidal nanoparticles showing notably attention-grabbing for the preparation of reference methods within the absence of added ions and capping brokers.
Tags:
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Leave a Reply

Your email address will not be published. Required fields are marked *